Use case 2 seeks to demonstrate how real-world data (RWD) can contribute to answering questions that are not typically answered by clinical trials, due to ethical or practical issues. These questions need to be answered for regulatory evaluation and health technology assessment (HTA), in the improvement of external validity, statistical power, and precision.
- For breast cancer, a synthetic population is being created representing men with breast cancer (the population often neglected in randomised controlled trials (RCT)).
- In the scope of rare and lethal phenotypes such as Amyotrophic Lateral Sclerosis (ALS), there is a need for external control arm to complement single-arm trials, to increase inference robustness to improve HTA and reimbursement decisions.
Therefore, in Use Case 2 we are examining and displaying which types of RWD can serve as high-quality external control arms (i.e., description of feasibility and data quality), and which methods and standards should be applied to encourage transparency as replicability in RWD use for study design purposes.